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Abstract: Lower urinary tract symptoms suggestive of benign prostatic hyperplasia 
(LUTS/BPH) are common in aging men and can signiﬁ  cantly affect quality of life. Men with 
bothersome LUTS/BPH often present with various other age-related conditions, including sexual 
dysfunction, heart disease, hypertension, diabetes, and the metabolic syndrome, which can 
complicate management decisions. Therefore, healthcare providers should be familiar with 
ﬁ  rst-line treatment options for LUTS/BPH and their differing safety proﬁ  les, particularly with 
respect to cardiovascular and sexual function side effects. This article presents a review of 
ﬁ  rst-line medical therapy options for managing aging men with LUTS/BPH and patient con-
siderations when evaluating and selecting these therapies, with a focus on the clinical efﬁ  cacy 
and cardiovascular and sexual function safety proﬁ  les of the uroselective α1-adrenergic receptor 
antagonist alfuzosin 10 mg once daily. Alfuzosin improves LUTS, peak urinary ﬂ  ow rates, and 
disease-speciﬁ  c quality of life, reduces the long-term risk of overall BPH progression, and is well 
tolerated in aging men, with minimal vasodilatory and sexual function side effects, even in those 
with comorbidities. Alfuzosin is well tolerated when used in combination with antihypertensive 
medications and phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. 
The long-term clinical efﬁ  cacy and good cardiovascular and sexual function safety proﬁ  le of 
alfuzosin can contribute to an improved quality of life for aging men with LUTS/BPH.
Keywords: alfuzosin, lower urinary tract symptoms, benign prostatic hyperplasia, aging, 
cardiovascular system, sexual function
Introduction
Over the next 50 years, life expectancy is estimated to rise steadily to a mean of 
80 years for men in more developed countries (2004a). By 2050, it is estimated that 
there will be more than 38 million men aged 65 years or older in the United States and 
more than 7 billion worldwide (US Census Bureau 2004b, 2007). With this increase 
in longevity comes a greater risk for age-related diseases, including benign prostatic 
hyperplasia (BPH). Histological BPH is found in approximately 50% of men aged 
51–60 years and in approximately 90% of men aged 81–90 years (Figure 1) (Berry 
et al 1984). It is estimated that about half of men with histological BPH will develop 
moderate-to-severe lower urinary tract symptoms (LUTS), deﬁ  ned as a score of more 
than 7 points on the American Urological Association (AUA 2003) Symptom Index 
or International Prostate Symptom Score (IPSS), including urinary urgency, increased 
urinary frequency, nocturia, insufﬁ  cient bladder emptying, and weak or hesitant urinary 
ﬂ  ow (AUA 2003). Interestingly, the severity of LUTS in men with BPH does not cor-
relate with prostate size or the level of urethral obstruction (Jacobsen et al 1995).
LUTS suggestive of BPH (LUTS/BPH) have a considerable impact on the patient’s 
quality of life. In a large, longitudinal cohort study of US health professionals, men Clinical Interventions in Aging 2008:3(3) 512
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with severe LUTS showed a greater impairment of general 
health status than those with gout, hypertension, angina, or 
diabetes (Welch et al 2002). Similarly, in the Olmsted County 
study, there was clear evidence that moderate-to-severe LUTS 
strongly impaired the daily lives of men aged 40–79 years in 
terms of degree of bother, interference with daily activities, 
degree of worry, psychological general well-being, and general 
health (Girman et al 1994). LUTS/BPH can be even more both-
ersome due to a strong association between LUTS severity and 
sexual dysfunction, as consistently demonstrated by various 
large-scale epidemiological studies (Rosen et al 2005). Sexual 
dysfunction, including erectile dysfunction (ED) and ejacula-
tory dysfunction (EjD), is strongly associated with LUTS after 
controlling for age, comorbidities, and lifestyle factors (Rosen 
et al 2003; Li et al 2005). The causality of this association is 
currently not known, but autonomic hyperactivity/increased 
sympathetic tone, alterations in the Rho/Rho kinase pathway 
regulating smooth muscle contraction, endothelial (nitric oxide 
synthase/nitric oxide) dysfunction, atherosclerosis-induced 
pelvic ischemia, and age-related hormone imbalances may 
play a role (Rosen et al 2005; McVary 2006).
BPH is often a progressive disease, predominantly 
characterized by a deterioration of LUTS over time, but 
also by the occurrence of serious outcomes, including acute 
urinary retention (AUR; a painful inability to pass urine 
that requires catheterization) and the need for BPH-related 
surgery (eg, transurethral resection of the prostate [TURP]) 
(Emberton et al 2003). Because LUTS/BPH is a common 
age-related disorder (Berry et al 1984), patients with LUTS/
BPH often present with other conditions that increase in 
prevalence with increasing age, including sexual dysfunction 
(ED and EjD), heart disease, hypertension, diabetes, and the 
metabolic syndrome (ie, concurrent metabolic risk factors of 
abdominal fat, atherogenic dyslipidemia, hypertension, insu-
lin resistance or hyperglycemia, a prothrombotic state, and a 
proinﬂ  ammatory state) (Figures 2–5) (Feldman et al 1994; 
Ford et al 2002; Rosen et al 2003; CDC 2004a, b, c). 
The presence of concomitant age-related conditions in men 
with bothersome LUTS/BPH can pose a signiﬁ  cant manage-
ment challenge. Therefore, healthcare providers should be 
familiar with ﬁ  rst-line treatment options for LUTS/BPH and 
their differing safety proﬁ  les, particularly with respect to 
cardiovascular and sexual function side effects.
The purpose of this review is to describe medical therapy 
options for managing aging men with LUTS/BPH and 
patient considerations when evaluating and selecting these 
therapies, with a focus on the clinical efﬁ  cacy and cardiovas-
cular and sexual function safety proﬁ  les of the uroselective 
α1-adrenergic receptor antagonist alfuzosin 10 mg once 
daily. Relevant English-language articles on the efﬁ  cacy, 
cardiovascular safety, or sexual function safety of alfuzosin 
10 mg were identiﬁ  ed via MEDLINE searches. Abstracts 
presented at recent meetings, US prescribing information for 
alfuzosin and other BPH medical therapies, and the current 
American Urological Association (AUA) BPH Guideline 
(AUA 2003) were also searched.
LUTS/BPH management
The primary goals of therapy for men with bothersome LUTS 
are to improve symptoms and improve quality of life (AUA 
2003). In addition, each patient’s risk for disease progression 
and the serious complications of BPH (eg, refractory AUR, 
bladder stone, recurrent urinary tract infection, hematuria, or 
renal insufﬁ  ciency) should be considered when selecting a 
BPH treatment option, with the beneﬁ  ts and side effects of 
each treatment assessed and discussed with the individual 
patient. Risk factors for BPH progression and serious com-
plications include increased age, severe LUTS, a high serum 
prostate-speciﬁ  c antigen (PSA) level, prostate size 30 mL, 
a low urinary ﬂ  ow rate, and a high postvoid residual urine 
volume (Roehrborn et al 2000, 2002; Crawford et al 2006; 
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Figure 1 Prevalence of histological benign prostatic hyperplasia (BPH) as a function 
of age (drawn from data of Berry et al 1984).
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Figure 2 Prevalence of erectile dysfunction as a function of age (drawn from data 
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Roehrborn 2006b) Other factors that need to be addressed 
when selecting the most appropriate BPH treatment option 
are the patient’s comorbidities, concomitant medications, 
and sexual activity/sexual function. For some patients, the 
cost of therapy can also be an important issue (Harkaway and 
Issa 2006).
Irritative/storage and obstructive/voiding LUTS can 
be bothersome to many men with BPH. Therefore, the 
quantiﬁ  cation of LUTS and their associated bother with the 
AUA Symptom Index (identical to the IPSS) and the IPSS 
bother question, respectively, are recommended by the 2003 
AUA Guideline on BPH management for determining dis-
ease severity and providing a basis for discussions of BPH 
treatment options (AUA 2003). The 2003 AUA Guideline 
states that patients with mild BPH symptoms (AUA 
Symptom Index 7) and those with moderate-to-severe 
symptoms (AUA Symptom Index 8) that do not interfere 
with quality of life should be managed with watchful waiting 
(AUA 2003). Patients with bothersome moderate-to-severe 
BPH symptoms should be provided with information regard-
ing the beneﬁ  ts and risks of recommended BPH treatment 
options (ie, watchful waiting, medical therapy, minimally 
invasive therapy, and surgical therapy) (AUA 2003). Benchmark 
therapy for symptomatic BPH remains TURP. Surgical 
management may be selected if symptoms are particularly 
bothersome or if serious complications of BPH have devel-
oped. Only transurethral microwave thermotherapy (TUMT) 
and transurethral needle ablation (TUNA) are recommended 
in the 2003 AUA Guideline as minimally invasive options 
for the partial relief of LUTS in the standard patient (2003). 
In many patients with LUTS/BPH, ﬁ  rst-line medical therapy 
with α1-adrenergic antagonists (α1-blockers), 5α-reductase 
inhibitors (5ARIs), or α1-blocker plus 5ARI combination 
therapy can provide adequate alleviation of LUTS with fewer 
and less serious side effects than invasive therapies (2003).
LUTS/BPH medical therapies
α1-Blockers
By inhibiting smooth muscle α1-adrenergic receptors, 
α1-blockers (ie, alfuzosin, doxazosin, tamsulosin, and 
terazosin) relax prostatic and bladder neck smooth muscle 
and partially relieve LUTS by improving bladder outlet 
obstruction. These medications have a rapid onset of action 
(within a few days for improving LUTS) and are considered 
the most effective monotherapy for the relief of LUTS, 
irrespective of prostate size. Alfuzosin, doxazosin, and 
terazosin are quinazoline derivatives, whereas tamsulosin 
is a sulfonamide derivative. Alfuzosin, doxazosin, tam-
sulosin, and terazosin have comparable clinical efﬁ  cacy 
(ie, 4- to 6-point improvement in the AUA Symptom Index, 
2- to 3-mL/s increase in the peak urinary ﬂ  ow rate, and 
1- to 1.5-point improvement in the bother score), but differ in 
their side-effect proﬁ  les (AUA 2003). The main side effects 
associated with α 1-blockers are orthostatic hypertension, diz-
ziness, headache, asthenia, rhinitis, and EjD. Rare instances 
of hypersensitivity, priapism, palpitations, and edema also 
have been reported. The older non-uroselective α1-blockers, 
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Figure 3 Prevalence of ejaculatory dysfunction as a function of age (drawn from 
data of Rosen et al 2003).
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Figure 4 Prevalence of hypertension, heart disease, and diabetes in US men as a 
function of age (drawn from data of NHANES III (CDC 2004a, b, c).
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Figure 5 Prevalence of the metabolic syndrome in US men as a function of age 
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doxazosin and terazosin, require dose titration because of 
ﬁ  rst-dose vasodilatory effects. The uroselective α 1-blockers 
alfuzosin and tamsulosin affect the lower urinary tract to a 
greater extent than the cardiovascular system, require no 
dose titration, and allow convenient once-daily dosing. The 
results of 2 large randomized studies (MTOPS and ALTESS) 
have shown that doxazosin and alfuzosin reduce the risk 
of overall BPH progression, mainly by reducing the risk 
for LUTS deterioration (McConnell et al 2003; Roehrborn 
2006a). In a study in which the cost effectiveness of watchful 
waiting, medical therapy (α1-blockers, 5ARIs, or combination 
therapy), TURP, and TUMT in the treatment of BPH was 
evaluated, α1-blockers and TURP were the most cost-
effective therapies, from a US payer perspective, for 
patients with moderate and severe LUTS, respectively 
(DiSantostefano et al 2006).
5α-Reductase inhibitor (5ARI) 
monotherapy and combination therapy
Unlike α1-blockers, which alleviate LUTS by relaxing 
smooth muscle, 5ARIs inhibit the conversion of testosterone 
to dihydrotestosterone, thereby inducing glandular atrophy 
and prostate shrinkage while preventing any further pros-
tate growth. According to the 2003 AUA Guideline, 5ARIs 
(ie, dutasteride and ﬁ  nasteride) and combination therapy with 
an α1-blocker and a 5ARI are appropriate medical therapies 
for men with LUTS and demonstrable prostate enlargement 
(AUA 2003). 5ARIs are less effective than α1-blockers in 
relieving LUTS, providing a 3- to 4-point improvement in the 
AUA Symptom Index, a 2- to 2.5-mL/s increase in the peak 
urinary ﬂ  ow rate, and a 1-point improvement in the bother 
score and their onset of action for relieving LUTS is typically 
6–12 months. In appropriate BPH patients, 5ARI therapy 
can reduce the risk of AUR and the need for BPH-related 
surgery (McConnell et al 2003). Disadvantages of 5ARI 
therapy include sexual function side effects (ie, hypoactive 
sexual desire, EjD, and ED). Although short-term studies 
(1 year) have demonstrated no additional improvements in 
the AUA Symptom Index and the peak urinary ﬂ  ow rate for 
combination therapy over α1-blocker monotherapy (Lepor 
et al 1996; Debruyne et al 1998; Kirby et al 2003), a 5-year 
study of combination therapy with doxazosin and ﬁ  nasteride 
demonstrated a signiﬁ  cantly reduced risk of overall BPH 
progression (ie, increase in AUA Symptom Index of 4 
points and increased occurrence of AUR, urinary inconti-
nence, renal insufﬁ  ciency, or recurrent urinary tract infection) 
when compared with doxazosin or ﬁ  nasteride monotherapy 
(McConnell et al 2003). In addition, AUR and BPH-related 
surgery were signiﬁ  cantly reduced with combination therapy 
when compared with placebo. The beneﬁ  ts of combination 
therapy should be weighed against the combined side effects 
of both drugs and the cost associated with the long-term use 
of 2 drugs.
Mechanism of action of α1-blockers 
in the treatment of LUTS/BPH
α1-Blockers are a ﬁ  rst-line medical therapy for LUTS/BPH. 
Adrenergic receptors are involved in the regulation of cardio-
vascular, genitourinary, and central nervous system function. 
The second-generation (alfuzosin, doxazosin, and terazosin) 
and third-generation (tamsulosin) α1-blockers used for the 
treatment of LUTS/BPH demonstrate greater selectivity 
for α1-adrenergic receptors than α2-adrenergic receptors 
(mediators of cardiovascular regulation and the central ner-
vous system effects of α2-adrenergic agonists). The leading 
hypothesis is that the blocking of α1-adrenergic receptors 
causes relaxation of smooth muscle in the prostate gland and 
bladder neck, thereby improving urine ﬂ  ow and LUTS. Unlike 
doxazosin and terazosin, which were initially developed for 
the treatment of hypertension, alfuzosin and tamsulosin are 
considered clinically uroselective, meaning that each agent 
affects the prostate gland to a greater extent than the vascular 
system, thereby minimizing blood pressure effects.
Three known subtypes of α1-adrenergic receptors 
(α1A, α1B, and α1D) are expressed differentially in various human 
tissues. In the human prostate gland, approximately 70% of 
the α1-adrenergic receptors are the α1A subtype, with lower 
levels of the α1B and α1D subtypes (Lepor et al 1993; Testa 
et al 1993). Contraction of the human prostate is mediated 
predominantly by the α1A-adrenergic receptor subtype (Michel 
and Vrydag 2006), whereas α1B-adrenergic receptors are 
thought to play an increasing role in the control of blood pres-
sure in individuals aged 65 years and older (Rudner et al 1999). 
α1D-Adrenergic receptors predominate in the human bladder 
dome and spinal cord. Alfuzosin, doxazosin, and terazosin 
demonstrate equal afﬁ  nity/selectivity for the 3 α1-adrenergic 
receptor subtypes of the prostate, whereas tamsulosin exhib-
its selective binding to the α1A and α1D receptor subtypes 
versus the α1B receptor subtype. The α1A/α1B selectivity ratio 
of tamsulosin has been estimated as 20:1 compared with 
0.33–0.43:1 for alfuzosin, doxazosin, and terazosin (Fogler 
et al 1995). The clinical uroselectivity of tamsulosin is thought 
to result from its binding afﬁ  nity/selectivity for α1-adrenergic 
receptor subtypes (Lowe 2004). The clinical uroselectivity of 
alfuzosin is thought to result from its preferential distribution 
to the prostate gland versus blood (Martin et al 1997; Clinical Interventions in Aging 2008:3(3) 515
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Martin et al 1998; Mottet et al 2003) and its limited ability to 
penetrate the blood-brain barrier (Martin 1999).
Alfuzosin pharmacology
Alfuzosin is a quinazoline derivative that differs from the other 
3 α1-blockers indicated for the treatment of LUTS/BPH by the 
absence of a piperidine moiety and the presence of a diamino-
propyl spacer. The once-daily formulation of alfuzosin 10 mg, 
the Geomatrix® delivery system, is composed of 3 distinct 
layers, a hydrophilic matrix core of active drug and 2 inac-
tive layers that regulate the release of active drug over time 
(McKeage and Plosker 2002; Data on ﬁ  le, Sanoﬁ  -Aventis). 
The tablet initially swells, with slow gastric diffusion of 30% 
of the alfuzosin dose, followed by constant diffusion of 40% 
of alfuzosin in the small intestine, and ﬁ  nal dissolution in the 
colon of the remaining 30% of alfuzosin (Data on ﬁ  le, Sanoﬁ  -
Aventis). The bioavailability of alfuzosin 10 mg tablets under 
fed conditions is 49%, with the extent of absorption 50% 
lower under fasting conditions (Uroxatral® 2006). As a result, 
alfuzosin should be taken after a meal.
The time to the maximum plasma concentration is reached 
approximately 8 hours after a single dose of alfuzosin (Uroxatral® 
2006). Alfuzosin is predominantly metabolized by the liver, 
with only 11% of the alfuzosin dose eliminated in the urine as 
unchanged drug. The apparent elimination half-life of alfuzosin 
is 10 hours. In elderly patients with BPH, no relationship was 
demonstrated between peak plasma concentrations of alfuzosin 
and patient age. However, trough levels are 35% higher in patients 
aged 75 years (Uroxatral® 2006). Because of a reduction 
in plasma apparent clearance that results in higher plasma 
concentrations in patients with hepatic insufﬁ  ciency compared 
with healthy subjects, alfuzosin is contraindicated in men with 
moderate or severe hepatic impairment. No dosage modiﬁ  cation 
is required for patients with renal insufﬁ  ciency, but data are 
limited for those with severe renal insufﬁ  ciency (Uroxatral® 
2006). Care should be taken when prescribing alfuzosin to men 
with symptomatic hypotension or with a previous hypotensive 
response to other medications (Uroxatral® 2006).
Alfuzosin clinical efﬁ  cacy
Short-term (3-month) studies
The clinical efﬁ  cacy of alfuzosin 10 mg once daily in the 
treatment of LUTS/BPH has been extensively studied in men 
evaluated in clinical-trial and practice-based settings, including 
those aged 65 years and older, those with hypertension, and 
those taking anti-hypertensive medications. In a randomized, 
placebo-controlled, crossover study of men with symptomatic 
BPH, a single dose of alfuzosin 10 mg caused a signiﬁ  cant 
increase in the peak urinary ﬂ  ow rate (Qmax; 3.2 mL/s) compared 
with placebo (1.1 mL/s) as soon as 8 hours after dosing and 
lasting for at least 4 days (Marks et al 2003). This increase 
in Qmax occurred at the same time as the known peak plasma 
concentration of drug (Uroxatral® 2006). A subsequent ran-
domized, double-blind, placebo-controlled study of men with 
symptomatic BPH demonstrated that 7 days of treatment with 
alfuzosin 10 mg results in rapid symptom relief and increases 
in Qmax, with these improvements maintained during 1 month 
of treatment (Resnick and Roehrborn 2007). The results of a 
pooled analysis of data from 3 pivotal, randomized, double-
blind, placebo-controlled studies also suggested a rapid onset 
of action of alfuzosin 10 mg, with signiﬁ  cant improvements in 
LUTS and Qmax at their ﬁ  rst assessment (28 days and 14 days of 
treatment, respectively) (Roehrborn et al 2003). A more recent 
3-month, open-label study conducted in a clinical-practice 
setting has also indicated a rapid onset of action of alfuzosin 
10 mg in men with LUTS/BPH (Saad et al 2005). At 3 months 
of alfuzosin treatment, the IPSS improved 7.1 points (41%) 
from baseline, quality of life improved 1.5 points (38%) from 
baseline, and nocturia improved in 60% of men with nocturia 
at baseline, with these improvements predominantly occurring 
by the ﬁ  rst assessment at 9 days of treatment.
In the three pivotal, randomized, double-blind, placebo-
controlled studies, 3 months of treatment with alfuzosin 10 mg 
once daily signiﬁ  cantly improved both irritative (frequency, 
urgency, and nocturia), and obstructive (incomplete voiding, 
interrupted urine stream, weak urine stream, and difﬁ  culty 
initiating urination) LUTS, Qmax, and disease-speciﬁ  c quality 
of life compared with placebo treatment in men with symp-
tomatic BPH (van Kerrebroeck et al 2000; Roehrborn 2001; 
Nordling 2005) (Roehrborn et al 2003) (Table 1). In the 
pooled analysis of these 3 studies, the proportion of patients 
with a 3-point improvement in the IPSS was 76% during 
3 months of treatment with alfuzosin compared with 62% 
for placebo (p  0.001) (Roehrborn et al 2003).
In a recent randomized, double-blind, placebo-controlled 
study, no signiﬁ  cant change in total prostate volume or 
transition zone volume was demonstrated with transurethral 
ultrasound measurements during 3 months of treatment with 
alfuzosin (combined 10-mg and 15-mg groups) compared 
with placebo treatment (Roehrborn 2006c). Additional 
investigation of prostate volume changes after long-term 
treatment with alfuzosin is ongoing.
Long-term (9-month) studies
The long-term effectiveness of alfuzosin 10 mg once daily 
treatment in men with LUTS/BPH has been demonstrated Clinical Interventions in Aging 2008:3(3) 516
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in an open-label extension phase of a 3-month pivotal study 
(Van Kerrebroeck et al 2002), in a 2-year clinical-practice 
study (ALF-ONE; (Elhilali et al 2006)), and a 2-year study 
of BPH clinical progression (ALTESS; (Roehrborn 2006a)). 
In the ALFORTI pivotal study (Van Kerrebroeck et al 2002), 
patients randomized to receive alfuzosin 10 mg once daily or 
alfuzosin 2.5 mg 3 times daily during the double-blind phase 
received alfuzosin 10 mg for up to 9 months in the extension 
phase, whereas patients randomized to receive placebo dur-
ing the double-blind phase received alfuzosin 10 mg for up 
to 9 months in the extension phase. The improvements from 
baseline in LUTS, Qmax, and disease-speciﬁ  c quality of life 
observed during double-blind treatment with alfuzosin were 
maintained in the 9-month extension phase of the study. For 
all patients, LUTS improved 46%, Qmax improved 24%, and 
disease-speciﬁ  c quality of life improved 36% over baseline 
values at the end of the extension phase (all p  0.0001; 
Table 2) (Van Kerrebroeck et al 2002).
In the ALF-ONE study (Elhilali et al 2006), in which 
the efﬁ  cacy and safety of alfuzosin 10 mg once daily were 
evaluated in men with LUTS/BPH in a clinical-practice 
setting over a 2-year period, LUTS improved 39% and dis-
ease-speciﬁ  c quality of life improved 43% from baseline 
(both p  0.0001; Table 2). The majority of men reported 
symptom relief within 2 weeks of treatment initiation that 
was maintained throughout the study. Overall, 77% of the 
men had an improvement in the IPSS of 3 points and 50% 
had a 6-point improvement during alfuzosin treatment, 
with both irritative and obstructive symptoms signiﬁ  cantly 
improved. After 2 years of treatment with alfuzosin, the 
percentage of men with nocturia (ie, waking 3 times/
night to urinate) decreased from 44% at baseline to 14% 
(p  0.001). These results in a clinical-practice setting 
demonstrate the long-term efﬁ  cacy of alfuzosin 10 mg and 
indicate that the efﬁ  cacy observed in short-term clinical trials 
is maintained for at least 2 years.
The long-term effects of alfuzosin 10 mg once daily 
treatment on BPH clinical progression (ie, occurrence of ﬁ  rst 
AUR episode, need for BPH-related surgery, IPSS worsening 
of 4 points, and overall BPH progression [AUR and/or 
surgery and/or LUTS worsening]) were evaluated in the 2-year, 
placebo-controlled ALTESS study (Roehrborn 2006a). In men 
at risk for BPH progression events, the cumulative incidence 
of overall BPH clinical progression was signiﬁ  cantly reduced 
26% during treatment with alfuzosin compared with that 
during placebo treatment (16.3% versus 22.1% for placebo; 
p  0.0001). The percentage of men with IPSS worsening 
by 4 points was signiﬁ  cantly reduced 30% during alfuzosin 
treatment compared with that during placebo treatment (11.7% 
versus 16.8% for placebo; p = 0.0013). The risk of the ﬁ  rst 
occurrence of AUR was not reduced with alfuzosin (2.1% 
versus 1.8% for placebo; p = 0.82) and the risk of BPH-
related surgery was reduced 22% with alfuzosin compared 
with placebo treatment (5.1% versus 6.5% for placebo), but 
this difference was not signiﬁ  cant (p = 0.18). During the 2-
year study, alfuzosin treatment signiﬁ  cantly improved the 
IPSS, disease-speciﬁ  c quality of life (IPSS bother), and Qmax 
compared with placebo (Table 2). These results from the 
placebo-controlled ALTESS study conﬁ  rm the long-term 
efﬁ  cacy of alfuzosin treatment in the relief of LUTS and the 
improvement of quality of life in men with BPH observed in 
open-label studies. In addition, ALTESS study data indicated 
that high baseline levels of serum PSA (3.9 ng/mL) predicted 
BPH-related surgery in both treatment groups and a high 
Table 1 Efﬁ  cacy of alfuzosin 10 mg once daily in 3-month, randomized, double-blind, placebo-controlled studies
Study Treatment N IPSSa p valueb QoL (IPSS
bother)a
p valueb Qmax (mL/s)a p valueb
van Kerrebroeck et al (2000) Alfuzosin 143 −7 0.002 −1.1 0.0008 2 0.03
Placebo 154 −5 −0.6 1
Nordling (2005) Alfuzosin 154 −7 (5) 0.007 NR 1.5c 0.02c
Placebo 153 −5 (6) 0.5c
Roehrborn (2001) Alfuzosin 170 −4 (5) 0.001 −0.7 (1.1) 0.002 1c 0.0006c
Placebo 167 −2 (6) −0.3 (1.1) 0c
Pooled analysis of 3 studies 
(Roehrborn et al 2003)
Alfuzosin 473 −6 (5) 0.001 −1.0 (1.1) 0.001 2 (4) 0.001
Placebo 482 −4 (6) −0.7 (1.1) 1 (3)
aValues represent mean (SD) change from baseline, unless noted otherwise.
bp value for mean change from baseline vs placebo.
cAs assumption of normality was rejected, median change from baseline value is provided and p value represents pairwise comparison with placebo.
Abbreviations: IPSS, International Prostate Symptom Score; NR, not reported; QoL, quality of life (IPSS bother question); Qmax, peak urinary ﬂ  ow rate.Clinical Interventions in Aging 2008:3(3) 517
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baseline post-void residual urine volume (93 mL) predicted 
IPSS worsening in the placebo group.
The results of a 6-month, open-label, clinical-practice 
study suggested that the response to treatment with alfuzosin 
10 mg is the strongest predictor of AUR and BPH-related 
surgery in men with LUTS/BPH (Emberton et al 2006). 
Alfuzosin treatment was associated with a low rate of AUR 
(0.5%) and BPH-related surgery (1.1%). However, men with 
a stable or worsening IPSS at 6 months of treatment had 
a signiﬁ  cantly increased risk for AUR (hazard ratio [HR] 
3.75, 95% CI 1.58−8.89) and BPH-related surgery (HR 
4.71, 95% CI 2.69−8.24); those with an IPSS bother score 
of 3 during treatment also had a signiﬁ  cantly increased 
risk for BPH-related surgery (HR 7.61, 95% CI 4.16−13.93) 
(Emberton et al 2006). Therefore, the response to treatment 
with alfuzosin may help in identifying patients at risk for 
unfavorable BPH outcomes.
No effect of age or hypertension
When men enrolled in the 3 pivotal studies of alfuzosin 10 mg 
were stratiﬁ  ed according to age 65 years and 65 years 
at baseline, no signiﬁ  cant effect of age was demonstrated 
on the mean change in the IPSS (−5.6 for men aged 65 
years; −5.4 for men aged 65 years) or the mean change in 
Qmax (1.9 mL/s for men aged 65 years; 1.7 mL/s for men 
aged 65 years) with alfuzosin 10 mg once daily treatment 
from that of the entire population (p = 0.67 and p = 0.39, 
respectively, for age-treatment interaction; Data on ﬁ  le, 
sanoﬁ  -aventis). In an open-label study of the effect of age 
on the efﬁ  cacy of treatment with alfuzosin 10 mg/day, 4018 
men with LUTS/BPH from general medical practices were 
stratiﬁ  ed into 4 age groups: 56 years, 56 to 65 years, 66 
to 75 years, and 75 years (Sanchez-Chapado et al 2000). 
A signiﬁ  cant mean improvement from baseline of 11 to 12 
points in the IPSS was demonstrated for all age groups after 
Table 2 Long-term efﬁ  cacy and safety of alfuzosin 10 mg once daily
ALTESS study (Roehrborn 2006a)* ALFORTI extension 
study (Van Kerrebroeck 
et al 2002)†
ALF-ONE study 
(Elhilali et al 2006)‡
Efﬁ  cacy variable Alfuzosin
(N = 749)
Placebo
(N = 757)
Alfuzosin
(N = 311)
Alfuzosin
(N = 839)
IPSS, Mean (SD) 19.2 (4.7) at baseline
−5.9 (6.9) change from 
baseline at month 24
p = 0.0017a
19.2 (4.7) at baseline
−4.7 (6.9) change from 
baseline at month 24
17.1 (3.6) at baseline
9.3 (5.5) at month 12
p  0.0001b
16 at baseline
9 (39% improvement) 
at month 24
p  0.001b
QoL (IPSS bother), mean (SD) 3.8 (1.1) at baseline
−1.3 (1.5) change from 
baseline at month 24
p  0.001a
3.8 (1.1) at baseline
−0.9 (1.6) change from 
baseline at month 24
3.3 (0.9) at baseline
2.1 (1.2) at month 12
p  0.0001b
3.8 at baseline
2.0 (43% improvement) 
at month 24
p  0.001b
Qmax (mL/s), mean (SD) 8.9 (2.0) at baseline
2.0 (3.8) change from 
baseline at month 12
p = 0.001a
8.8 (2.0) at baseline
1.3 (3.6) change from 
baseline at month 12
9.1 (2.0) at baseline
11.3 (4.2) at month 12
p  0.0001b
NR
Adverse event, n (%) (N = 754) (N = 761) (N = 360) (N = 839)
Vasodilation
Dizziness 45 (6) 35 (5) 9 (3) 26 (3)
Headache 25 (3) 17 (2) 5 (1) 10 (1)
Syncope 5 (1) 2 (1) 1% 4 (1)
Hypotension 9 (1) 4 (1) 10 (3) 8 (1)
Malaise
Sexual function
1 (1) 0 4 (1) 2 (1)
Impotence 
(erectile dysfunction)
15 (2) 14 (2) 1% 12 (1)
Ejaculation disorder 3 (1) 0 2 (1) 3 (1)
*2-year, randomized, double-blind study; †3-month double-blind plus 9-month, open-label study; ‡2-year, open-label study.
ap value for mean change from baseline vs placebo.
bp value for mean (SD) change from baseline.
Abbreviations: IPSS, International Prostate Symptom Score; NR, not reported; QoL, quality of life (IPSS bother); Qmax, peak urinary ﬂ  ow rate.Clinical Interventions in Aging 2008:3(3) 518
Roehrborn and Rosen
2 months of treatment with alfuzosin, with both irritative and 
obstructive LUTS improving signiﬁ  cantly when compared 
with baseline values. In addition, signiﬁ  cant mean improve-
ments in the IPSS bother score of 2–3 points were shown 
for all age groups after 2 months of treatment with alfuzosin 
when compared with baseline values (Sanchez-Chapado et al 
2000). The results of this study in a clinical-practice setting 
are in agreement with those of clinical trials indicating that 
age does not affect the clinical efﬁ  cacy of alfuzosin 10 mg. 
Thus, alfuzosin 10 mg is an effective treatment for LUTS/
BPH in aging men, including the elderly. Pooled data from 
the 3 pivotal studies of alfuzosin 10 mg also demonstrated 
that the changes in IPSS and Qmax with alfuzosin treatment 
were comparable in men with hypertension (diastolic blood 
pressure 90 mmHg) and those without hypertension (dia-
stolic blood pressure 90 mmHg; p = 0.19 and p = 0.87, 
respectively, for hypertensive status-treatment interaction 
(Data on ﬁ  le, sanoﬁ  -Aventis).
Role in AUR management
A 2-phase, randomized, double-blind, placebo-controlled 
study (ALFAUR) evaluated the effect of alfuzosin 10 mg 
treatment on the outcome of a trial without catheter after 
a ﬁ  rst occurrence of AUR related to BPH (McNeill and 
Hargreave 2004; McNeill et al 2005). In phase I of the study, 
360 men with a ﬁ  rst episode of AUR secondary to BPH 
received alfuzosin 10 mg or placebo for 3 days before a trial 
without catheter (McNeill and Hargreave 2004; McNeill 
et al 2005). Alfuzosin treatment signiﬁ  cantly improved the 
rate of a successful trial without catheter (62% for alfuzosin 
versus 48% for placebo; p = 0.012). In phase II of the study, 
all patients who successfully voided after catheter removal 
received either alfuzosin 10 mg or placebo for 6 months 
(McNeill et al 2005). Alfuzosin treatment was associated 
with a 61% (p = 0.04 versus placebo), 52% (p = 0.04 versus 
placebo), and 29% (p = 0.20 versus placebo) reduction in 
the risk for BPH surgery at 1, 3, and 6 months, respectively. 
The combined rate of successful trial without catheter during 
phase I and no BPH-related surgery during 6 months of treat-
ment during phase II was 39% for men receiving alfuzosin 
versus 25% for those receiving placebo (p = 0.02) (McNeill 
et al 2005). Based on data from the ALFAUR study, alfuzosin 
treatment during hospitalization for the ﬁ  rst occurrence of 
AUR and after a successful trial without catheter resulted 
in signiﬁ  cant cost savings during the ﬁ  rst 6 months when 
compared with placebo treatment and with immediate 
prostate surgery (both p  0.05) (Annemans et al 2005). 
Alfuzosin is approved for the adjuvant treatment of AUR 
in more than 50 countries, but is not currently approved for 
this indication in the United States. Additional large-scale 
studies are needed to evaluate the role of alfuzosin in the 
management of BPH-related AUR.
Alfuzosin tolerability and safety
The tolerability and safety proﬁ  les of the different α1-blockers 
are important considerations when selecting a medication 
for the long-term management of LUTS/BPH in aging 
men. Many of the side effects of some α1-blockers (eg, diz-
ziness, orthostatic hypotension, syncope) are related to the 
blood pressure lowering effects of these medications. These 
vasodilatory side effects have the potential to cause falls, 
broken bones, hospitalization for serious injuries, and insti-
tutionalization (Morris and Wagg 2007). A meta-analysis of 
placebo-controlled studies has indicated that the incidence 
rates of dizziness and orthostatic hypotension with alfuzosin 
10 mg and tamsulosin 0.4 mg treatment are similar to or 
only slightly greater than those with placebo, whereas these 
incidence rates are generally higher with doxazosin and 
terazosin treatment than with placebo (Djavan and Marberger 
1999). In controlled clinical trials, the incidence of myocar-
dial infarction, angina pectoris, and death for men treated 
with alfuzosin 10 mg was low and typical of that of control 
middle-aged or older men (Data on ﬁ  le, Sanoﬁ  -Aventis). 
Sexual function also should be assessed and discussed with 
men before selecting a treatment option for managing both-
ersome LUTS/BPH and when evaluating the response to 
treatment. Alfuzosin 10 mg once daily, with its tolerability 
and good cardiovascular and sexual function safety proﬁ  les, 
can contribute to an improved quality of life for aging men 
with LUTS/BPH, including the elderly and those with other 
common age-related comorbidities.
Cardiovascular proﬁ  le
In the three pivotal studies of alfuzosin 10 mg, no ﬁ  rst-dose 
vasodilatory side effects were observed with alfuzosin treat-
ment and the incidence of patient withdrawal was comparable 
in the alfuzosin (9%) and placebo groups (10%) (Roehrborn 
et al 2003). The incidence of vasodilation-related side 
effects ranged from 6% to 15% with alfuzosin compared 
with 2%–9% with placebo (van Kerrebroeck et al 2000; 
Roehrborn 2001; Nordling 2005) (Table 3). Dizziness was 
the most common side effect in the placebo group (3%) and 
the alfuzosin group (5%). The incidence of vasodilatory side 
effects was comparable for elderly (7%) and younger (6%) 
men and for hypertensive (8%) and normotensive (5%) men 
who received alfuzosin 10 mg. Patients with mild or moderate Clinical Interventions in Aging 2008:3(3) 519
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renal insufﬁ  ciency taking alfuzosin 10 mg did not experience 
more vasodilatory side effects than patients taking placebo 
or patients with normal renal function (van Kerrebroeck et al 
2000). Pooled data from the 3 pivotal studies indicated no 
signiﬁ  cant change from baseline in systolic or diastolic blood 
pressure measurements during alfuzosin or placebo treatment 
(Roehrborn et al 2003). The effects of alfuzosin on blood 
pressure (Table 4) and heart rate in the 3 pivotal studies of 
alfuzosin 10 mg were small, comparable to placebo, and not 
considered clinically relevant (Roehrborn et al 2003). The 
maximum mean decrease from baseline was −2 mmHg for 
both men receiving alfuzosin and those receiving placebo. 
Changes from baseline in blood pressure measurements were 
comparable for elderly men and men with hypertension in the 
2 treatment groups (Table 4). Importantly, the incidence of 
asymptomatic orthostatic hypotension (ie, a decrease in sys-
tolic blood pressure of 20 mmHg upon standing) was low 
and similar in the alfuzosin and placebo groups (Roehrborn 
et al 2003). Long-term treatment with alfuzosin 10 mg once 
daily did not alter the side effect proﬁ  le or the cardiovascular 
safety proﬁ  le of alfuzosin (Table 2) (Van Kerrebroeck et al 
2002; Elhilali et al 2006; Roehrborn 2006a). Long-term 
treatment with alfuzosin 10 mg did not increase the incidence 
of orthostatic hypotension for men taking antihypertensive 
medications or for men with mild-to-moderate renal impair-
ment (Van Kerrebroeck et al 2002).
Table 3 Vasodilatory and sexual function side effects of alfuzosin 10 mg once daily in randomized, double-blind, placebo-controlled 
studies
van Kerrebroeck et al 
(2000)
Nordling (2005) Roehrborn (2001) Pooled analysis of 3 studies 
(Roehrborn et al 2003)
Alfuzosin 
(N = 143)
Placebo 
(N = 154)
Alfuzosin 
(N = 154)
Placebo 
(N = 153)
Alfuzosin 
(N = 176)
Placebo 
(N = 175)
Alfuzosin 
(N = 473)
Placebo 
(N = 482)
Adverse event, n (%)
Vasodilation
  Dizziness 3 (2) 2 (1) 9 (6) 6 (4) 13 (7) 5 (3) 25 (5) 14 (3)
 Headache 2  (1) 1 (1) 3 (2) 5 (3) 9 (5) 4 (2) 14 (3) 10 (2)
 Syncope NR NR 0 0 NR NR 1 (1) 0
 Hypotension 1 (1) 0 0 0 6 (3) 6 (3) 2 (1) 0
 Malaise 2  (1) 0 0 0 NR NR NR NR
Sexual function
   Impotence (erectile 
dysfunction)
0 1 (1) 2 (1) 0 5 (3) 2 (1) 7 (1) 3 (1)
  Ejaculation disorder 0 0 2 (1) 0 1 (1) 0 3 (1) 0
NR = not reported.
Table 4 Mean (SD) blood pressure effects of alfuzosin 10 mg once daily in randomized, double-blind, placebo-controlled studies
All patients Elderly (65 y) patients Hypertensive patients
Baseline Change at 
3 months
n (%) Baseline Change at 
3 months
AOHa, 
n (%)
Baseline Change at 
3 months
n (%)
SBP
  Alfuzosin 136 (17) –2 (15) 138 (17) –1 (15) 143 (16) –2 (18)
  Placebo 138 (17) –1 (15) 142 (17) –2 (15) 147 (18) –3 (17)
DBP
  Alfuzosin 82 (10) –1 (9) 81 (10) –1 (10) 86 (10) –2 (10)
  Placebo 83 (10) –2 (10) 83 (9) –0.2 (9) 88 (11) –2 (9)
AOHa
  Alfuzosin 10 (2) 5 (2) 1 (1)
  Placebo 8 (2) 2 (1) 5 (4)
Adapted from Roehrborn et al (2003).
aDecrease in SBP of 20 mm Hg when changing from a supine to an upright position.
Abbreviations: AOH, asymptomatic orthostatic hypotension; DBP, diastolic blood pressure (supine); SBP, systolic blood pressure (supine).Clinical Interventions in Aging 2008:3(3) 520
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In the clinical practice setting, large-scale studies have 
demonstrated that the cardiovascular safety proﬁ  le of alfuzosin 
10 mg is not affected by age, cardiovascular comorbidity, and 
anti-hypertensive comedications. In a study of 6,523 men with 
LUTS/BPH who were treated with alfuzosin for 6 months, the 
incidence of vasodilatory side effects was did not differ signiﬁ  -
cantly among age quartiles (ie, 60 years, 60–64 years, 65–70 
years, and 70 years), between men with and those without 
cardiovascular comorbidity (ie, hypertension, ischemic heart 
disease, or diabetes mellitus), or between men taking and 
those not taking antihypertensive medications (ie, diuretics, 
β-blockers, angiotensin-converting enzyme inhibitors, angio-
tensin II inhibitors, or calcium channel blockers) (Figure 6) 
(Hartung et al 2006). Furthermore, despite the increased 
prevalence of cardiovascular comorbidity and increased use of 
antihypertensive medications with age, no signiﬁ  cant changes 
from baseline in blood pressure measurements and heart 
rate were demonstrated among the different age groups after 
6 months of alfuzosin treatment. Mean changes from baseline 
in blood pressure measurements (decreases of 3 mmHg) 
and heart rate (increase of 1 beat/minute) were modest in men 
with and those without cardiovascular comorbidity and in 
men taking and those not taking antihypertensive medications 
(Hartung et al 2006). The good cardiovascular safety proﬁ  le 
of alfuzosin 10 mg during long-term treatment in a clinical 
practice setting was conﬁ  rmed in the 2-year ALF-ONE study 
and the 2-year ALTESS study, which demonstrated that the 
incidence of vasodilatory side effects and blood pressure 
changes from baseline were marginal and not signiﬁ  cantly 
affected by age (65 years), hypertension, or antihypertensive 
comedication (Elhilali et al 2006; Roehrborn 2007).
Finally, in a small study in 18 healthy, middle-aged men, 
no hemodynamic interactions were observed between alfuzosin 
10 mg once daily and the phosphodiesterase type 5 inhibitor 
tadalaﬁ  l 20 mg (Giuliano et al 2006). In an open-label study of 
men with BPH who were treated with alfuzosin 10 mg once daily 
and tadalaﬁ  l 20 mg (as needed, but no more than twice weekly), 
no signiﬁ  cant change in blood pressure measurements or the 
side effect proﬁ  le was observed over a 1-month period when 
compared with either monotherapy (Yassin and Diede 2003). 
Preliminary results of a post-marketing surveillance study of 
men with ED who were treated with vardenaﬁ  l indicated that 
the type and incidence of side effects were similar in those 
taking and those not taking alfuzosin (Van Ahlen et al 2005). 
Current US labeling for sildenaﬁ  l, tadalaﬁ  l, and vardenaﬁ  l 
states that these phosphodiesterase type 5 inhibitors should be 
started at the lowest recommended dose for patients stabilized 
on α-blocker therapy, whereas α-blocker therapy should be 
started at the lowest recommended dose for patients already 
taking sildenafil, tadalafil, or vardenafil (Cialis® 2005; 
Levitra® 2005; Viagra® 2006). Placebo-controlled studies 
are needed to evaluate optimal management approaches for 
concomitant LUTS/BPH and ED.
Sexual function proﬁ  le
Sexual activity is common among older men (Diokno et al 
1990; Lindau et al 2007) and is an important component of 
quality of life for aging men (Rosen et al 2003). The majority 
of men between the ages of 50 and 75 years report that they 
are sexually active, but many of these men are bothered by 
sexual problems, including sexual dysfunction. Because of 
BPH treatment-related sexual side effects and the known 
strong association between LUTS and sexual dysfunction, 
the effects of BPH medical therapies on sexual function 
are an important consideration when selecting the most 
appropriate BPH treatment and when monitoring men on 
BPH treatment. For example, tamsulosin has demonstrated a 
dose-related incidence of EjD (8% for tamsulosin 0.4 mg and 
18% for tamsulosin 0.8 mg versus 0.2% for placebo) in US 
placebo-controlled studies (Flomax® 2006). Recent results 
of studies in healthy male volunteers have indicated that 
tamsulosin treatment results in decreased ejaculate volume 
or anejaculation (Hisasue et al 2005; Hellstrom and Sikka 
2006), possibly due to peripheral effects of tamsulosin on 
the seminal vesicles and vas deferens and central effects of 
tamsulosin on serotonin and dopamine receptors that play 
a role in ejaculation. In each of the 3 placebo-controlled 
pivotal studies of alfuzosin 10 mg, the incidence of sexual 
function side effects during treatment with alfuzosin was 
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Figure 6 Incidence of vasodilatory side effects during treatment with alfuzosin 10 
m g once daily according to age, comorbidities, and antihypertensive comedications 
(drawn from data of Hartung et al 2006).
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low and comparable to that with placebo treatment (Table 3) 
(van Kerrebroeck et al 2000; Roehrborn 2001; Nordling 
2005). The pooled analysis of data from the 3 pivotal 
studies indicated that the incidences of ED and EjD were 
1% and 0%, respectively, with alfuzosin compared with 
1% and 1%, respectively, with placebo during 3 months of 
treatment (Roehrborn et al 2003). Alfuzosin 10 mg also has 
been shown to have minimal effects on sexual function dur-
ing long-term treatment (Table 2) (Van Kerrebroeck et al 
2002; Elhilali et al 2006; Roehrborn 2006a). Interestingly, 
data from a preliminary open-label study of 3076 men with 
LUTS/BPH demonstrated that alfuzosin 10 mg treatment for 
1 year led to signiﬁ  cant improvements from baseline in both 
ED and EjD (each p  0.001) (van Moorselaar et al 2005). 
The mean improvements from baseline in ED and EjD were 
greater in men with severe LUTS than in those with mild or 
moderate LUTS at baseline. Direct comparator studies are 
needed to further evaluate differences in the sexual function 
safety proﬁ  les of the different α1-blockers used in the treat-
ment of LUTS/BPH.
Many aging men with symptomatic BPH are manag-
ing concomitant ED with oral phosphodiesterase type 5 
inhibitors (ie, sildenaﬁ  l, tadalaﬁ  l, vardenaﬁ  l). Moreover, 
the adrenergic nervous system appears to play a role in the 
pathophysiology of both ED and BPH. The results of studies 
of combination treatment with alfuzosin 10 mg once daily 
and phosphodiesterase type 5 inhibitors in men with ED and 
BPH have suggested a synergistic beneﬁ  cial effect of these 
medications on ED, EjD, and LUTS. In a 12-week pilot 
study of the efﬁ  cacy and safety of combination therapy with 
alfuzosin 10 mg and sildenaﬁ  l 25 mg once daily in men with 
previously untreated LUTS/BPH and ED, the improvement 
in LUTS from baseline was greater with combination treat-
ment (24%) than with either medication alone (alfuzosin 
16%; sildenaﬁ  l 17%) (Kaplan et al 2007). The frequency 
of urination, nocturia, and Qmax signiﬁ  cantly improved with 
alfuzosin and combination therapy, whereas no signiﬁ  cant 
improvement in these parameters was demonstrated with 
sildenaﬁ  l monotherapy. Erectile function improved with both 
sildenaﬁ  l (50%) and alfuzosin (17%) monotherapy, but the 
greatest improvement was demonstrated with combination 
therapy (59%) (Kaplan et al 2007). There was no evidence of 
hypotension or syncope during 12 weeks of treatment with 
alfuzosin plus sildenaﬁ  l combination therapy. The possibility 
of a synergistic effect of alfuzosin 10 mg once daily and 
tadalaﬁ  l 20 mg (on demand 20–60 minutes before sexual 
activity) in the treatment of LUTS and ED was also sug-
gested by the results of an open-label study of 42 men with 
LUTS/BPH and ED who were previously unresponsive to 
tadalaﬁ  l monotherapy (Yassin and Diede 2003). During 
6 months of combination therapy, LUTS and ED improved, 
with 71% of the men reporting improved erectile func-
tion. The side-effect proﬁ  le associated with alfuzosin plus 
tadalaﬁ  l combination therapy was comparable to that with 
each monotherapy. Additional studies are needed to evaluate 
the beneﬁ  cial effects of alfuzosin on sexual function in men 
with LUTS/BPH.
The 25-item Male Sexual Health Questionnaire (MSHQ) 
(Rosen et al 2004) and a 4-item short form of the MSHQ 
(MSHQ-EjD Short Form) (Rosen et al 2007a) have been 
validated as self-administered instruments for assessing 
sexual function in aging men. The MSHQ, which includes 
a 7-item ejaculatory function domain, provides an in-depth 
assessment of ejaculatory function and differentiates between 
men with LUTS and EjD and healthy men (Rosen et al 2004). 
The MSHQ-EjD Short Form, with 3 ejaculatory function 
items and 1 ejaculation bother item, differentiates between 
men with none/mild LUTS and those with moderate/severe 
LUTS and is useful for assessing EjD in clinical practice and 
research settings (Rosen et al 2007a). Both the MSHQ and 
the MSHQ-EjD Short Form have demonstrated sensitivity for 
detecting treatment-related effects in men with LUTS/BPH 
enrolled in the BPH Registry and Patient Survey (Rosen 
et al 2007b).
Intraoperative ﬂ  oppy iris syndrome (IFIS)
Cataract is an age-related condition that affects more than 
20 million adults aged 40 years or older in the US, including 
nearly 8 million men (National Eye Institute 2002). The 
occurrence of intraoperative ﬂ  oppy iris syndrome (IFIS) 
during cataract surgery has been reported in men with BPH 
who were treated with tamsulosin, but not in those treated 
with α1-blockers without α1-adrenergic receptor subtype 
selectivity (Chang and Campbell 2005; Oshika et al 2007). 
It was suggested that tamsulosin-induced IFIS may be due 
to inhibition of the predominant α1A-adrenergic receptor in 
the iris that regulates dilator smooth muscle tone (Chang and 
Campbell 2005). In a recent retrospective comparative study 
of 35 men who reported exclusive use of either tamsulosin or 
alfuzosin at their initial evaluation visit for cataract surgery, 
men who used tamsulosin had a signiﬁ  cantly higher risk 
for IFIS relative to those who used alfuzosin (adjusted odds 
ratio = 32.25, 95% CI 2.74–377.11) after adjusting for dura-
tion of α1-blocker use, diabetes mellitus, and hypertension 
(Blouin et al 2007). Results from in vivo studies in rabbits 
demonstrated that alfuzosin, doxazosin, tamsulosin, and Clinical Interventions in Aging 2008:3(3) 522
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terazosin inhibit phenylephrine-induced mydriasis at doses 
similar to those required to inhibit phenylephrine-induced 
increases in intraurethral pressure, whereas higher doses 
are needed to inhibit pupil contraction in the absence of 
phenylephrine (Michel et al 2006). Based on these results, 
the authors concluded that the ocular risk of tamsulosin is 
comparable to other α1-blockers. Although additional studies 
are needed to determine the safety of α1-blockers with respect 
to the development of IFIS during cataract surgery, treatment 
with an α1-blocker should be stopped at least 1 week before 
cataract surgery and phenylephrine should not be used to 
induce mydriasis.
Alfuzosin clinical utility in aging men
α1-Blockers, including alfuzosin, are a first-line medi-
cal therapy for LUTS/BPH. Alfuzosin 10 mg once daily 
requires no dose titration and has a rapid onset of action, 
making it convenient and easy to use by elderly men, espe-
cially after a missed dose. Alfuzosin 10 mg tablets, with 
the Geomatrix® delivery system, break down and release 
drug at a constant rate over time. Alfuzosin, doxazosin, 
tamsulosin, and terazosin have similar efﬁ  cacy proﬁ  les with 
respect to improvements in LUTS and Qmax, but their safety 
proﬁ  les, especially relating to their cardiovascular toler-
ability and sexual function side effects, are different. These 
safety proﬁ  le differences may be related to pharmacologic 
differences among the 4 α1-blockers, particularly their 
blood-brain barrier penetration and α1-adrenergic receptor 
subtype selectivity. The efﬁ  cacy of alfuzosin in relieving 
symptomatic BPH is not affected by age, cardiovascular 
comorbidity, or antihypertensive comedications, so it is an 
effective treatment option for the long-term management of 
LUTS/BPH in elderly men. Alfuzosin has a favorable safety 
proﬁ  le, with minimal cardiovascular and sexual function 
side effects. The cardiovascular safety proﬁ  le of alfuzosin 
in elderly men is comparable to that in younger men. As 
sexual activity is common and an important component 
of quality of life in many aging men, healthcare providers 
should consider the effects of the different medical therapies 
for LUTS/BPH on sexual function, both erectile function 
and ejaculatory function. Alfuzosin effectively relieves the 
irritative and obstructive urinary symptoms of BPH with-
out any negative effects on sexual function, whereas other 
drugs in this class can be associated with sexual function 
side effects. Long-term alfuzosin treatment reduces overall 
LUTS progression compared with placebo and may help 
to select patients at risk for serious BPH outcomes. Impor-
tantly, alfuzosin and the other α1-blockers that demonstrate 
equal afﬁ  nity/selectivity for the 3 α1-adrenergic receptor 
subtypes appear to be associated with a very low incidence 
of IFIS during cataract surgery relative to that observed with 
tamsulosin, further suggesting that α1-adrenergic receptor 
subtype selectivity may be responsible for various treatment-
related side effects during tamsulosin therapy.
Conclusions
Aging men with LUTS/BPH are at increased risk for the 
development of several other age-related diseases, includ-
ing sexual dysfunction, heart disease, diabetes, and the 
metabolic syndrome. All of these conditions, which can 
negatively affect quality of life, need to be considered 
when evaluating and selecting BPH treatment options. 
The currently available α1-blockers, alfuzosin, doxazosin, 
tamsulosin, and terazosin, demonstrate equal clinical effec-
tiveness in relieving LUTS suggestive of BPH (a 4–6 point 
improvement in IPSS; a 2–3 mL/s increase in Qmax; and a 
1–1.5 point improvement in the IPSS bother score), but dif-
fer with respect to their cardiovascular and sexual function 
safety proﬁ  les. Alfuzosin 10 mg once daily is effective in 
improving LUTS, Qmax, and disease-speciﬁ  c quality of life, 
reduces the long-term risk of LUTS progression, and is well 
tolerated in aging men with BPH, with minimal vasodilatory 
side effects, even in those with hypertension, heart disease, 
and diabetes and those taking antihypertensive medications. 
Alfuzosin also has no deleterious effect on sexual function 
and is well tolerated when used in combination with low 
doses of phosphodiesterase type 5 inhibitors for the treatment 
of ED. Studies suggest that alfuzosin and phosphodiesterase 
type 5 inhibitors may act synergistically to improve both 
LUTS and sexual function, but the tolerability of higher 
doses of phosphodiesterase type 5 inhibitors is not known. 
The efﬁ  cacy and tolerability of alfuzosin 10 mg once daily are 
similar in elderly and younger patients. The long-term clinical 
efﬁ  cacy and the cardiovascular and sexual function safety 
proﬁ  les of alfuzosin 10 mg once daily can contribute to an 
improved quality of life for aging men with LUTS/BPH.
Disclosures
CGR has been an investigator for and a consultant to Sanoﬁ   
Aventis.
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